Worldwide market for immunology therapies to exceed $74 billion by 2022; Report

Despite the imminent patent expiry of many therapies, the global immunology treatment market is set to expand, from $61.5 billion in 2015 to reach $74.2 billion in 2022, new research indicates.

According to business intelligence provider GBI Research’s latest report, the immunology treatment market’s compound annual growth rate (CAGR) will equal a relatively stable 2.71%, due to practical and regulatory barriers to entry for biosimilars that are not present for small molecule generics, and a moderately strong late-stage pipeline.

Dominic Trewartha, managing analyst for GBI Research, says: “This market is a lucrative area as up to 7% of western populations are thought to be affected by chronic immunological disorders. Consequently, the pharmaceutical pipeline for immunology is considerable, with 1,896 products currently in active development. While 85 of these are in Phase III of the process, it must be acknowledged that 73% of these pipeline products are in early developmental stages.”